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Background: Reducing smoking prevalence is a public health priority that can save more lives and money than
almost any other known preventive intervention. Internet interventions have the potential for enormous public
health impact given their broad reach and effectiveness. However, most users engage only minimally with even the
best designed websites, diminishing their impact due to an insufficient ‘dose’. Two approaches to improve
adherence to Internet cessation programs are integrating smokers into an online social network and providing free
nicotine replacement therapy (NRT). Active participation in online communities is associated with higher rates of
cessation. Integrating smokers into an online social network can increase support and may also increase utilization
of cessation tools and NRT. Removing barriers to NRT may increase uptake and adherence, and may also increase
use of online cessation tools as smokers look for information and support while quitting. The combination of both
strategies may exert the most powerful effects on adherence compared to either strategy alone.
Methods/Design: This study compares the efficacy of a smoking cessation website (WEB) alone and in conjunction
with free NRT and a social network (SN) protocol designed to integrate participants into the online community.
Using a 2 (SN, no SN) x 2 (NRT, no NRT) randomized, controlled factorial design with repeated measures at baseline,
3 months, and 9 months, this study will recruit N = 4,000 new members of an internet cessation program and
randomize them to: 1) WEB, 2) WEB + SN, 3) WEB + NRT, or 4) WEB + SN + NRT. Hypotheses are that all
interventions will outperform WEB and that WEB + SN + NRT will outperform WEB + NRT and WEB + SN on 30-day
point prevalence abstinence at 9 months. Exploratory analyses will examine theory-driven hypotheses about the
mediators and moderators of outcome.
Discussion: Addressing adherence in internet cessation programs is critical and timely to leverage their potential
public health impact. This study is innovative in its use of a social network approach to improve behavioral and
pharmacological treatment utilization to improve cessation. This approach is significant for reducing tobacco’s
devastating disease burden and for optimizing behavior change in other arenas where adherence is just as critical.
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Tobacco use is the leading cause of preventable death in
the United States, causing 443,000 premature deaths
among adults and nearly $200 billion in total economic
burden each year [1]. Currently, 20.4% of adults smoke,
and reductions in smoking prevalence have stalled in re-
cent years [2]. Accelerating the reduction in the popula-
tion prevalence of smoking will require innovative
approaches to reach and treat current smokers [3-5].
The internet is a promising delivery channel for
tobacco cessation interventions that has the potential for
enormous public health impact (reach x efficacy; [6,7]).
The majority of U.S. adults are internet users [8], and
internet use continues to expand through all segments
of the U.S. population [9], especially among rural
populations, racial/ethnic minorities, and lower income
groups that are at disproportionate risk for smoking. Re-
cent reports indicate 6 to 9% of all internet users in the
United States - more than 10 million adults - search for
assistance in quitting smoking each year [10,11]. The
internet is well-suited to deliver the core elements of
evidence-based cessation treatment [12]: 1) Practical
counseling (problem solving/skills training) information
and feedback can be tailored and produced immediately;
2) Social support from peers and experts can be
provided in online communities; and 3) Information
about pharmacotherapy can be provided, with tailored
guidance for medication selection and dosing. Internet
treatment can be accessed 24/7 - particularly at relapse-
sensitive times - and used as long as a smoker desires.
The costs of internet programs are relatively fixed,
resulting in greater efficiency as use increases. Studies
have shown quit rates of 7 to 26% at 6 months [13-19]
and recent meta-analyses support its effectiveness
[20,21]. A ‘dose response’ relationship between intensity
of use (for example, number of visits, duration of use)
and higher abstinence rates has also been demonstrated
[13,14,22-26]. The internet is not a panacea for reaching
or treating all smokers, but its current use among
millions of smokers provides an extraordinary opportun-
ity to increase population cessation rates.
Despite this enormous potential, however, the impact
of internet cessation interventions is yet to be realized
given the challenges of poor adherence. Adherence is
traditionally defined as ‘the extent to which a person’s
behaviour corresponds with agreed recommendations
from a health care provider’ [27]. Since internet
interventions have no specified prescriptions for use, ad-
herence in this context may best be defined as ‘the ex-
tent to which individuals experience the content of the
intervention’ [28] or more simply ‘use of the eHealth
intervention over time’ [29]. Adherence is measured by
website utilization metrics which may include the num-
ber of logins a participant makes during a specific periodof time, the number of days between registration and
last login as a measure of duration of use, the number of
interactive features used, and the number of modules or
materials read [29,30]. A consistent finding - across
internet cessation programs and study populations - is
that most users engage only minimally with even the
most popular, field-tested websites [22,24,31-33]. Most
users visit only one to two times and do not use many of
the interactive tools, community support, or pharmaco-
therapy that can promote abstinence. Also referred to as
engagement [16,34-38], persistence [39], non-usage attri-
tion [40,41], and exposure [42,43] in a growing number
of eHealth research studies, the problem of adherence
has been observed across internet studies [28,41,44].
Low levels of adherence in internet programs is not a
phenomenon unique to one or two sites, but rather an
aspect of this treatment modality that has yet to be
understood or fully addressed [30].
The purpose of this study is to test two independent
strategies - and their interaction - to improve quit rates
through greater adherence to the evidence-based
components of cessation treatment (practical counseling,
social support, pharmacotherapy). Increasing adherence
to these treatment components could result in an extra-
ordinary increase in population rates of cessation.
Promoting adherence to cessation treatment via social
network effects
One approach to increasing adherence in internet cessa-
tion programs - and improving treatment outcomes -
lies within online social networks. Data from several
sources demonstrate powerful links between participa-
tion in online social networks, web-based treatment ad-
herence, and improved outcomes [13,37,45]. For
example, Cobb et al. [13] found that a composite meas-
ure of website utilization intensity (number of logins x
duration in minutes per login) was highly correlated
with use of support resources (that is, number of emails
sent and received, number of people an individual sent
email to and received email from), suggesting that
greater website use was largely a function of involvement
in the online community. Individuals who participated
in the community were almost three times as likely to
have quit three months later (odds ratio = 2.71) and four
times more likely to be continuously abstinent for two
months or more (OR = 4.08) as compared to less inten-
sive users, even after controlling for motivation. Quitters
were more likely to have posted in forums, made an on-
line buddy, and sent or received internal email than
those who did not quit. An et al. [45] found that weekly
peer emails may have contributed to significantly higher
cessation website utilization throughout a 20-week
smoking cessation study with college students. More re-
cently, Richardson et al. [24] reported that compared to
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on BecomeAnEX.org, those who used it one time were
1.7 times more likely to be abstinent, and those who
used it two or more times were 2.2 times more likely to
be abstinent even after controlling for general utilization
(visits) and a broad range of demographic, smoking, and
psychosocial covariates. An observational study by
Poirier and Cobb [37] found that participants with social
ties in a web-based program to improve well-being
showed higher levels of engagement as measured by
website visits, opening program emails, and completing
program challenges.
Unfortunately, only a small percentage of users engage
in online cessation communities either actively (that is,
sending messages, posting in forums) or passively (that
is, reading posts by others, viewing profiles) [26,31,46].
Since social support is a key component of cessation
[47-50] and participation in an online social network
may yield important benefits for cessation, it is import-
ant to investigate how to increase the percentage of
users who benefit from these interactions.
This study uses a social network approach - proactive,
directed, and personalized outreach from within an on-
line community - to increase the proportion of new
members that participate in and become integrated into
an existing online social network. The approach centers
on social networking, defined as the formation of ties
[51] and evidenced by reciprocal communications be-
tween members. While there are robust associations be-
tween social network factors and improved health
outcomes [52,53], there are few reports of network
interventions in which ties between individuals are
modified or manipulated to effect behavior change
[54,55]. Network interventions may work by targeting
individuals based on their position within the network,
or by modifying the social networking process to alter
the structure of the network. Social processes such as
smoking cessation are thought to exhibit a threshold
[56] or complex contagion effect [57,58] where social in-
fluence increases non-linearly as additional contacts
adopt (or drop) the behavior of interest. This study is
based on the premise that increasing the number of ties
among members of an online network may enhance a
range of behavior changes (for example, repeat visits to
a website, community participation, sustained NRT use,
cessation), particularly in individuals who start with no
connections and might otherwise form few or no
connections within the network.
Promoting adherence to cessation treatment via free NRT
A second strategy to improve adherence in the
evidence-based elements of cessation treatment is to
provide smokers with access to NRT free of charge. Al-
though NRT doubles the chances of successful cessationand is a proven quitting strategy [12,59,60], the vast ma-
jority of smokers do not use NRT when quitting [61,62].
Among the small percentage of smokers that do use
NRT, the majority does not follow recommended usage
guidelines for duration and/or dosage [63-65]. Providing
smokers with free or reduced-cost NRT has been shown
to increase initial uptake (that is, trial of NRT) [66,67].
Importantly, providing smokers with free NRT may also
increase utilization of the practical counseling tools and
social support available in an internet cessation program.
It may induce smokers to make a quit attempt [66] dur-
ing which they may be more likely to make use of inter-
net tools to plan for cessation, to assist them in setting a
quit date, and to help them learn how to cope with crav-
ing and withdrawal symptoms. They may also be more
likely to turn to current and former smokers in an on-
line community for guidance through the cessation
process and for information about medication dosing or
side effects. There may also be reciprocal and interactive
effects, with greater internet cessation program use
leading to greater NRT adherence and vice versa. Several
randomized trials have examined the combined efficacy
of internet cessation treatment and NRT on abstinence
[18,63,68,69]. No study that we are aware of has specific-
ally addressed whether providing NRT free of charge in
conjunction with internet cessation can improve cessa-
tion outcomes through greater adherence to the problem
solving/skills training, pharmacological, and social sup-
port components of treatment.
Aims
The overarching goal of this study is to test the individ-
ual and combined effects of two potentially complemen-
tary strategies to improve adherence to the evidence-
based elements of cessation treatment: 1) leveraging
powerful social network effects for behavior change, and
2) providing access to an initial course of free nicotine
replacement therapy. Primary Aim 1 is to evaluate the
comparative efficacy of WEB + SN, WEB + NRT, and
WEB + SN + NRT versus WEB alone with regard to
self-reported 30-day point prevalence abstinence at the
primary endpoint of 9 months and at secondary
endpoint of 3 months. We hypothesize that all three
intervention conditions will outperform WEB and that
WEB + SN + NRT will outperform WEB + SN and
WEB + NRT. Primary Aim 2 is to examine whether the
impact of treatment condition on cessation is mediated
by greater adherence to problem solving/skills training
tools, social support via the community, and pharmaco-
therapy (see Figure 1). We hypothesize that WEB + SN
+ NRT will have the greatest impact on treatment adher-
ence, which will yield higher quit rates than the other
treatments. Exploratory analyses will examine whether
social support and social norms are active elements in
Figure 1 Research model. Theoretical model depicting the intervention components, main outcome variable, and mediating variables.
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known mediators of abstinence such as self-efficacy.
Methods/Design
Study design
This study is a randomized controlled trial that uses a 2
(SN, no SN) x 2 (NRT, no NRT) factorial design to com-
pare four treatment conditions in a repeated measures
design: WEB, WEB + SN, WEB + NRT, and WEB + SN
+ NRT. Assessments occur at baseline, at 3 months, and
at 9 months, with 30-day self-reported point prevalence
abstinence at 9 months as the primary outcome. Self-
reported smoking status is a commonly accepted out-
come measure in web-based cessation trials
[14,16,18,19,22,23,70]. Biochemical verification of abstin-
ence is not feasible on a national sample enrolled
through the internet. Furthermore, misreporting of ab-
stinence is expected to be low for several reasons: low
demand characteristics of the interventions, the use of a
proactive recruitment strategy to recruit a representative
sample of smokers that do not have special consider-
ation that might elicit misreporting, the fact that partici-
pation is completely under the control of the
participants, and the use of an extended, 9-month
follow-up period [71-74]. We will verify smoking status
among a random sample of 10% of self-reported quitters
with an established protocol for verification by a signifi-
cant other. Study procedures from enrollment through
follow-up data collection are depicted in Figure 2. Thestudy is funded by the National Cancer Institute of the
U.S. National Institutes of Health (R01 CA155489-01A1).
Setting and participants
This is a web-based randomized trial. Participants are
new registered users of BecomeAnEX.org, a free, branded,
smoking cessation website developed in accordance with
the Clinical Practice Guidelines [9] and publicized, in part,
through a national multi-component mass media campaign
that launched in 2008 [75]. Eligibility criteria are current
smoking, age 18 years or older, and U.S. residence.
Exclusion criteria are contraindications to nicotine replace-
ment therapy (pregnant or breastfeeding, recent cardiac
problems, current nicotine replacement therapy use).
Recruitment
Recruitment is automated using a web-based clinical
trials management system. Immediately following regis-
tration on BecomeAnEX, participants are shown an invi-
tation that briefly describes the study. Interested
participants complete an online screening form that
includes questions about smoking status (current,
former, never), motivation to change (planning to quit in
the next 30 days, next 6 months, not planning to quit),
demographic variables (gender, age, ethnicity, race, edu-
cation), and contraindications to nicotine replacement
therapy (Are you pregnant or breast-feeding, or do you
plan to become pregnant in the next year? Do you have
heart disease, an irregular heartbeat, or high blood
Figure 2 Study procedures. Flowchart of study procedures from enrollment through follow-up data collection.
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had a heart attack in the past 3 months? Are you cur-
rently using any kind of stop smoking medication, such
as the nicotine patch, nicotine gum, nicotine lozenge or
nicotine spray, or prescription medications such as
Zyban/bupropion or Chantix/varenicline?). Eligible in-
dividuals are presented with the study consent form
and asked to provide online informed consent. Those
who consent to participate provide contact informa-
tion (name, email address, phone number). The base-
line survey is sent via email to this address and must
be completed within 24 hours. Participants are rando-
mized to treatment upon completion of the baseline
survey. No incentive is provided for enrollment in the
study. Recruitment volume is capped at a maximum of 10new enrollees per day to ensure a manageable workload
for intervention and research staff throughout the study
period.
Randomization
Randomization is stratified by gender and baseline mo-
tivation to quit. Within-strata randomization assignments
are automated using a computer algorithm.
Interventions
Group 1 (WEB)
Participants have full access to the BecomeAnEX website
which provides: 1) clear/strong advice to quit smoking;
2) assistance setting a quit date; 3) assessment of motiv-
ation and nicotine dependence; 4) problem-solving/skills
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5) assistance in selecting and using FDA-approved
pharmacotherapies; and 6) social support [24,75]. The
voice of the site is that of a former smoker that
empathizes with the challenges of quitting smoking and
‘Re-Learning’ life without cigarettes. BecomeAnEX
provides practical counseling, social support, and medi-
cation information as follows:
Practical counseling (problem-solving/skills training)
The Re-Learn Habit section includes a series of inter-
active modules and videos to help users set a quit date
and begin planning to quit by identifying effective/inef-
fective strategies from past quit attempts, removing
tobacco products from their environment, identifying
smoking triggers, and developing coping strategies. Ex-
tensive information is provided about how to avoid and
cope with relapse. Users are provided positive coping
alternatives for stress and cravings, informed about
triggers for relapse, encouraged to review their reasons
for quitting, and given advice on dealing with weight
gain and interpersonal conflict.
Social support
The Re-Learn Support section emphasizes the import-
ance of social support in the cessation process and
provides guidance on how to solicit helpful support from
family and friends. Members can also participate in the
BecomeAnEX community. Online communications can
take the form of a personal message sent directly be-
tween members, a public post on another member’s pro-
file page (‘wall’), a discussion forum post, a forum reply
to a previously posted message, or comments on a blog
post. The site has over 2,000 user-initiated discussion
forums and hundreds of messages are posted in the
community each day. Other social support elements in
the site include the ability to invite contacts from a per-
sonal email list to join the site, to search by member
name within the site, and to search for and read user
blogs. Clinical support blogs are posted by a tobacco
treatment expert from the Mayo Clinic. Clear guidelines
about appropriate community participation are provided.
Administrative support for technical issues is available
from the BecomeAnEX community manager and all
questions are addressed within 2 business days.
Pharmacotherapy
The Re-Learn Addiction section provides information
about nicotine addiction and FDA-approved medica-
tions. The information is presented in a series of short
streaming videos narrated by a physician. The physician
explains the process of nicotine addiction and addres-
ses the myths and realities of cessation medications
and how they work. Users are encouraged to use amedication in their quit attempt and to seek guidance
from their pharmacist or health care provider. All seven
FDA-approved cessation medications are discussed in
detail.
Group 2 (WEB + SN)
Participants receive proactive communications from
established members of the BecomeAnEX community
(‘Integrators’) designed to integrate them into the com-
munity. Two former smokers who are well-known,
longstanding, active members of the community serve in
this role. Using a secure, dedicated interface within
the study clinical trials management system, Integrators
are notified when new participants have been rando-
mized to this treatment arm. Within 24 hours, they post
a public message on the new member’s ‘wall’ within
BecomeAnEX to welcome them to the site, encourage
them to fill out their profile, or comment on some as-
pect of an existing profile. In communications with
participants, Integrators may use any of the following
approaches to engage participants: 1) pose open-ended
questions; 2) share their personal experience with smok-
ing and quitting; 3) recommend specific tools and
features of the website; 4) inquire about medication use
and the participant’s experience with a chosen medica-
tion; 5) monitor the participant’s profile to determine
when they have set a quit date and provide encourage-
ment around the quit date; 6) respond to any forum
posts by participants; and 7) suggest ‘friends’ or groups
within the community. Integrators are blind to treat-
ment condition in that they do not know whether
participants are also receiving NRT (Group 4). The goal
is for Integrators to have routine contact with parti-
cipants for at least 3 months, with ongoing communica-
tion with those who respond throughout the duration of
the study. Treatment duration of 3 months will provide
sufficient time to examine the effectiveness of the inte-
gration protocol and will also allow us to evaluate if the
effects are persistent at the 9-month follow-up. Each In-
tegrator spends approximately 1 to 2 hours per day in
this role.
Selection of the Integrators was based on analysis of
key social network metrics for an online cessation com-
munity [76]. Specifically, we identified two individuals
within the BecomeAnEX community who had: 1) been a
member for at least 6 months; 2) logged in within the
previous 2 weeks; 3) made 10 or more blog posts; 4)
friended at least 25 other members; 5) both posted and
received at least 500 wall comments; 6) posted at least
500 comments on blog posts; 7) joined 1 or more
groups; and 8) never received any flags for offensive con-
tent. Integrators completed a one-day training to
familiarize them with the aims and scope of the project,
and to review recent and planned updates and
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other lay person/peer interventions in which those
delivering the intervention are trained in the basics of
tobacco dependence treatment or counseling approa-
ches, the Integrators in this study did not receive any
formal training in tobacco dependence treatment. The
protocol is not designed to deliver tobacco dependence
treatment or advice; rather, the overarching goal is for
the Integrators to facilitate the integration of new mem-
bers into the BecomeAnEX online social network.
All communications are monitored by study staff, in-
cluding review of the timing, content, and tone for
outgoing communications. Integrators participate in
biweekly supervision meetings via teleconference.
Group 3 (WEB + NRT)
Participants are mailed a free 4-week supply of the NRT
product of their choice (patch, gum, or lozenge) within 3
days of randomization. The decision to provide 4 weeks
of free NRT (versus a full course of 8 to 12 weeks de-
pending on product type) was based on two factors: 1)
previous published studies have shown that adherence
to NRT remains an issue even when participants are
provided a full course of therapy [77] and that sending
more free NRT to smokers does not necessarily translate
into enhanced duration of use [78] or chances of quit-
ting and remaining smoke-free [79], and 2) we are
interested in examining whether providing a starter kit
of free NRT increases initial uptake (that is, any use)
and whether the information and resources provided on
BecomeAnEX.org increase overall adherence to NRT, in-
cluding purchase of additional product beyond the free
supply.
Participants are notified by email following
randomization that they have been assigned to a treat-
ment group that includes NRT and again when the prod-
uct has been shipped. NRT is provided as an over-the
-counter product (that is, with no additional support or
guidance provided) to parallel the experience subjects
would have if they purchased NRT on their own. A
printed calendar with study contact information is
included with the NRT shipment for participants to
mark the days they used the product.
Group 4 (WEB + SN + NRT)
Participants will have access to 4 weeks of NRT and the
SN protocol as described in the sections above.
Additional contact
Participants in Groups 1 (WEB) and 2 (WEB + SN) are
mailed a letter at the start of the study confirming that
they have been enrolled. This letter is to control for the
contact present in both NRT treatment arms (Groups 3
and 4) since participants in those conditions receive amailed package at the start of the study. The content of
the letter mirrors the calendar insert included in the
NRT mailing.Data collection
Data for the study are obtained through two sources: 1)
self-report assessments at baseline, at 3 months and at 9
months, and 2) online tracking software that records
utilization of BecomeAnEX. Online surveys are hosted
on a secure server at Legacy; all data transfer is
encrypted using SSL protocols. Mixed-mode follow-up
(online surveys, telephone for online non-responders;
[25]) is used to maximize follow-up rates. Mailed
reminders are sent prior to each follow-up. An email
with a link to the online survey is sent at 3 and 9
months post-randomization; non-respondents receive
reminders 3 and 6 days after the initial email. Individuals
who have not responded within 7 days are contacted by
telephone by professional telephone interviewers. Phone
surveys are conducted by research staff blind to treat-
ment condition. Participants are reimbursed via Amazon
or PayPal for survey completion ($20 for web survey,
$15 for phone survey). Individual level tracking metrics
of BecomeAnEX utilization (for example, number of
visits, page views, feature utilization) are recorded using
Adobe/Omniture SiteCatalyst [80] software.Measures
Brief measures with known psychometric properties
were selected when possible to minimize respondent
burden. Most measures listed below are standard
instruments commonly used in cessation treatment
studies, and are reliable when administered via the inter-
net [81,82] (see Table 1).Socio-demographic variables and health status
We gather information about age, sex, marital status,
race, ethnicity, employment, and education [83]. Using
the item from the Medical Outcomes Study 36-Item
Short-Form Health Survey (SF-36), participants rate
their current health status on a 5-point scale from 1
(excellent) to 5 (poor) [84]. Participants also indicate
whether they have ever had an illness caused or made
worse by smoking, and whether they have been ad-
vised by a healthcare provider to quit smoking in the
past year.Internet use
Frequency and duration of internet use [85], type of
internet connection [86], and the nature and frequency
of social media use [87] are measured using survey items
from the Pew Internet and American Life Project.
Table 1 Schedule of assessments











Perceived social support X X
Social norms X X
Treatment adherence mediators
General website utilization metrics X
Use of practical counseling tools X
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At baseline, current smoking and smoking history are
assessed using a brief standard questionnaire which
covers smoking frequency and rate; use of other tobacco
products; confidence and desire to quit smoking; and
quitting history including the number of quit attempts
in the previous year and any methods used. Motivation
to quit smoking is assessed at baseline and each follow-
up using the Stages of Change algorithm [88].
Fagerström Test for Nicotine Dependence (FTND)
The FTND is a continuous measure of dependence and
a standard instrument in the field [89].
NRT receptivity
Eleven questions administered at baseline address parti-
cipants’ perceptions of nicotine replacement products.
Items were adapted from existing instruments [90,91].
Participants rate their level of agreement with a series
of statements about NRT products using a Likert scale
(1 = strongly disagree; 2 = somewhat disagree; 3 = some-
what agree; 4 = strongly agree). Items include statements
such as ‘NRT products double the chance of quitting com-
pared to cold turkey’, ‘NRT products are too expensive’,
and ‘The nicotine in nicotine stop smoking products is
more dangerous than the nicotine in cigarettes.’NRT preference
During the baseline assessment - prior to randomiza-
tion - all participants indicate their preferred nicotine
replacement product, selecting from a list of nicotine
patch, nicotine gum, and nicotine lozenge and in-
dicating their preferred flavor for gum and lozenge
selections. Participants are reminded that not every-
one will receive NRT and that selection is completely
random.Behavioral intentions
Sixteen items were developed to measure behavioral
intentions related to the main intervention components.
At baseline, participants indicate the likelihood of doing
a specific action over the next 3 months using a Likert
scale (1 = No, I definitely will not; 2 = I probably will
not; 3 = I probably will; 4 = Yes, I definitely will). Items
include statements such as ‘Keep track of my cigarettes
on BecomeAnEX to identify smoking triggers,’ ‘Use
BecomeAnEX regularly (that is, at least a few times a
week),’ ‘Set a quit date,’ ‘Quit cold turkey without any
medicine or other assistance,’ and ‘Use nicotine replace-
ment therapy (NRT) like the patch or gum’. Psychomet-
ric analyses will be conducted to examine the factor
structure and internal validity of these items.
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To explore the influence of personality on adherence in
a social network, participants complete six of the ten
items of the Ten-Item Personality Inventory [92], a brief
measure designed to assess the constellation of traits
defined by the Five Factor Theory of Personality.
Participants indicate the extent to which six adjective
pairs describe themselves using 7-point ratings (1 = dis-
agree strongly to 7 = agree strongly): 1) extraverted, en-
thusiastic, 2) reserved, quiet, 3) anxious, easily upset, 4)
open to new experiences, complex, 5) calm, emotionally
stable, and 6) conventional, uncreative. These six items
correspond to three personality dimensions that have
been linked to social media use [93]: openness to experi-
ence (items 4 and 6), extraversion (items 1 and 2), and
emotional stability (items 3 and 5).
Self-efficacy
Smoking cessation self-efficacy is assessed using the
nine-item short form of the Smoking Situations Confi-
dence Questionnaire (SSCQ; [94]). The questionnaire
can be scored to form a total situation confidence index;
subscales measure confidence to resist smoking in pleas-
ant and unpleasant situations and in situations where
smoking is habitual.
Social support
The Appraisal and Belonging subscales of the 12-item
Interpersonal Support Evaluation List (ISEL; [95]) are
used to measure perceived availability of social resources
at baseline. The Appraisal subscale measures the
perceived availability of someone to talk to about one’s
problems; the Belonging subscale assesses the perceived
availability of people with whom to engage in activities.
Perceptions of cessation-related support are measured at
baseline and follow-up with an adapted version of the
Partner Interaction Questionnaire [81,82]. This ques-
tionnaire assesses receipt of positive behaviors (support-
ive of cessation) and negative behaviors (harmful to
cessation) from an individual who has followed the
participant’s efforts to quit smoking. Participants are also
asked how often they feel that there are people they can
turn to [96] as a measure of loneliness. Response options
are: 1 = Never; 2 = Rarely; 3 = Sometimes; 4 = Always.
Perceptions of BecomeAnEX specific online social sup-
port is measured at each follow-up with an adapted ver-
sion of the Online Social Support Scale for Smokers
(OS4; [97]), a 15-item measure that assesses various
dimensions of online support from a smoking cessation
community.
Social norms
Two questions were developed to measure perceived so-
cial norms related to the two main interventioncomponents (that is, participation in an online commu-
nity, NRT use). Smokers respond to two statements:
What do most smokers you know think about sharing
one’s personal experiences with quitting with other
people on the internet? What do most smokers you
know think about nicotine replacement therapy? Re-
sponse options are: 1 = They think it’s helpful for them
and for most other people too; 2 = They think it’s help-
ful for them but not for other people; 3 = They think it’s
not helpful for them but may be for other people; 4 =
They think it’s not helpful for them or for anyone else.
Outcome measures
Smoking status
We collect information on point prevalence smoking
status at all follow-ups. The primary outcome is self-
reported 30-day point prevalence abstinence measured
at 9 months. Secondary outcomes include motivation to
quit, number of 24-hour quit attempts, and continuous
abstinence.
Intervention satisfaction
Participants rate their overall satisfaction, perceived
helpfulness, and whether the website met their
expectations on a Likert scale (1 = not at all, 5 = ex-
tremely). We also ask whether participants received
any communications from other members of the
BecomeAnEX community, who they received commu-
nications from, and their perceptions of those com-
munications using ten adjectives (for example, genuine,
informative, intrusive, annoying).
Treatment adherence
General website utilization metrics
From BecomeAnEX we track the following general
utilization metrics: number of logins, minutes spent
using the site during each visit/session, number of
interactive features used, and number of days logged
in to the site as a measure of treatment duration.
Website utilization is recorded using Adobe/Omniture
SiteCatalyst. Every page view by a participant is re-
corded into a relational database, and page views are
grouped into sessions. The duration of a session is
defined as the time elapsed between the first page view
and the last page view in a given session. If a user does
not view a new page for more than 30 minutes, the sys-
tem marks them as inactive and their next return visit
creates a new session.
Utilization of practical counseling tools (problem solving/
skills training)
From BecomeAnEX we extract data on use of specific
features of the site related to practical counseling:
whether the user set a quit date, number of quit date
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coping strategies, number of medication-related videos
watched, and use of medication-related information.
Participation in online community
From BecomeAnEX we extract a number of metrics
related to participation in the online community: com-
pletion of the social support workbook exercise, number
of days between registration and community participa-
tion, number of wall posts made/received, number of
forum posts/replies, number of personal messages sent/
received, number of friends within the community, and
extent of community profile (for example, posted photo,
blog). All process data are stored in a relational database
with timestamps, allowing for the extraction of specific
events such as the viewing of a piece of content, the
formation of a friend tie, or the content of a specific
wall post.
Quit methods/pharmacotherapy use
At each follow-up, participants are asked about medica-
tion use and other quit methods. If participants visited a
physician/health professional, they are asked whether
they discussed quitting and if any cessation treatments
were offered or undertaken (for example, bupropion).
NRT adherence is measured at each follow-up with
items that assess dosage, smoking during usage, pur-
chase of additional NRT, and reasons for non-usage [79].
Ethical considerations
The overall risk of this study is judged to be minimal.
Participants randomized to receive nicotine replacement
therapy may experience side effects. An extensive litera-
ture has generally supported the safety of nicotine patch,
gum, and lozenge for healthy smokers and for distribu-
tion via population-based treatment modalities as long
as clients are screened adequately per labeling
instructions. This study encourages use of products that
are FDA-approved and sold over-the-counter, and
provides all product materials including the instructional
package insert. Participants who make a quit attempt
may experience withdrawal symptoms after quitting.
There is no reason to believe that participation in this
study would worsen nicotine withdrawal symptoms. The
overall severity of withdrawal discomfort should be
diminished among participants who choose to use NRT,
although medication will not necessarily eliminate with-
drawal discomfort entirely. In any case, withdrawal
symptoms tend to be short-lived, with most symptoms
abating within 1 to 2 weeks of quitting. Data security
and confidentiality are protected at all times. Institu-
tional Review Board approval for the study was provided
by Western Institutional Review Board (WIRB protocol
#20110887).Power analysis
Sample size is based on assumed quit rates of WEB =
10%, WEB + SN = 16.5%, WEB + NRT = 18%, and WEB +
SN + NRT = 26% at 9 months. Assuming a non-differen-
tial attrition rate of 25% at the 9-month follow-up, these
translate into Intent-To-Treat (ITT) quit rates of WEB =
7.5%, WEB + SN = 12.375%, WEB + NRT = 13.5%, and
WEB + SN + NRT = 19.5%. Based upon an extensive set
of simulations, we expect power to exceed 85% for all five
pair-wise contrasts required for testing the hypotheses of
Primary Aim 1 at a multiplicity-adjusted two-tailed signifi-
cance level of 1%, chosen to maintain the study-wide Type
I error rate at 5%.
Although our 2 x 2 factorial design naturally lends itself
to estimation and testing of a SN x NRT interaction, inter-
pretation of such interaction effects is highly dependent
on the choice of measurement scale. For example, our
assumed quit rates lead to synergistic interaction effects in
the probability scale (6.5% + 8.0% for the individual SN
and NRT treatments versus 16% assumed for the SN +
NRT combination therapy), but antagonistic interaction
effects in the odds ratio scale commonly used in logistic
regression (SN versus no SN ORs that equal 1.60 when
WEB + NRT is the reference group versus 1.78 when
WEB alone is the reference group, leading to an SN ×
NRT interaction OR = 0.90). Hence, we decided to focus
instead on a more clinically relevant inferential goal, that
is, establishing whether the combination treatment is su-
perior to either treatment alone, irrespective of the pres-
ence or absence of an interaction effect. However, to the
extent that the presence of such a SN x NRT interaction
(OR = 0.90) is of interest to the field, extensive simulation
established that it can be estimated and reported with a
moderate degree of precision given our planned sample
size. In particular, we can be 80% certain that the length of
the 95% confidence interval will not exceed 0.72 units in
the OR scale (for example, 95% CI = 0.60-1.32).
Statistical analysis plan
Preliminary analyses
The distributional properties of continuously scaled
variables will be examined to determine the need for
normalizing transformations. Next, we will determine
whether the groups show large standardized mean
differences at pre-treatment on demographic charac-
teristics, psychosocial variables, or smoking variables.
Although the large sample size (N = 4,000) should pre-
clude finite sample randomization imbalances, should
such between-group differences be found, we will cor-
rect for them via regression adjustment.
Outcome analyses
Our primary outcome for Aim 1 is self-reported 30-day
point prevalence abstinence (ppa). Differences in
Figure 3 Mediational model. Conceptual diagram depicting the
intervention (X), outcome (Y), and mediator (Z) variables as well as
theory (a), action (b), and outcome (c’) pathways which will be
examined in mediational analyses.
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evaluated at our primary endpoint of 9 months post-
randomization, as well as the secondary endpoint of 3
months post-randomization. To account for within-sub-
ject correlation due to the repeated-measures aspect of
our study, we will employ the Generalized Estimating
Equation (GEE), which extends generalized linear model
methodology to correlated data in PROC GENMOD of
SAS/STAT. Analyses will be conducted first using an ITT
principle, analyzing data from all subjects randomized to
treatment, counting as smokers those lost to follow-up
(missing = smoking). We will also conduct a Responder-
Only analysis that includes subjects reached at follow-up.
Analyses will be conducted in SAS (SAS Inc., Cary, North
Carolina, USA).
Moderator analyses
We will examine potential moderators of the
intervention-smoking cessation relationship (for ex-
ample, gender, baseline stage of motivational readiness,
nicotine dependence). Effect modification will be
conducted by analyzing interactions between treatment
and selected variables.
Mediator analyses
Primary Aim 2 hypothesizes that adherence mediates
the intervention-cessation relationship. We will establish
mediation using the MacKinnon approach [98]. As
explained in Cerin and MacKinnon [99] and imple-
mented by Papandonatos et al. [100], behavioral resear-
chers ought to determine whether: (a) the intervention
successfully acted upon the putative mediator (that is,
‘Action Theory test’); (b) changes in the mediator were
indeed predictive of changes in the target behavior
suggested by the conceptual framework underpinning the
intervention over and above any direct treatment effects
(that is, ‘Conceptual Theory test’); and (c) these conditions
held simultaneously for each mediator of interest, indi-
cating that the corresponding mediational pathway ac-
counted for at least part of the relationship between the
intervention and the target behavior (that is, ‘Mediation
test’). This corresponding mediation model is shown in
Figure 3. Here X is the exogenous variable (treatment), Z
is the hypothesized mediator (adherence), Y is the out-
come (abstinence or related change), a is the regression
path between treatment and the mediator (action theory
path), b is the regression path between the mediator and
the outcome (conceptual theory path), and c’ is the regres-
sion path between treatment and the outcome controlling
for the effect of the mediator (outcome path).
Missing data
We expect less than 25% missing data at any time. If a
participant refuses follow-up, we will censor the data atthe point of loss of contact. Under an ITT approach,
participants who had been considered non-smokers up
to the point of loss will be considered smokers at future
data points.
Discussion
Improving adherence in internet cessation programs is
critical to leverage the potential public health impact of
this ‘broad reach’ treatment modality. Internet inter-
ventions are a promising delivery channel for tobacco
cessation treatment that have the potential for enormous
public health impact (reach x efficacy). But the impact of
internet cessation interventions is yet to be realized
given the limited use of effective treatment components.
It is important to note that the focus of this study is not
on increasing internet use among all smokers; rather, the
focus is on testing specific methods to improve adher-
ence to proven components of cessation treatment for
smokers already using the internet to quit smoking. As
internet use continues to expand through all segments
of the U.S. population [9] - especially among rural
populations, racial/ethnic minorities, and lower income
groups at disproportionate risk for smoking - the poten-
tial of web-based interventions to reduce population
prevalence of smoking will become even more impor-
tant. Given the demonstrated reach of web-based in-
terventions to millions of smokers, it is critical that we
advance scientific understanding about how to engage
all users so that they receive the optimal dose of treat-
ment necessary for abstinence in order to realize the full
population impact of web-based interventions. The need
to improve adherence in cessation treatments is clear:
even the best treatment will have little impact if it is not
used.
This study is innovative in the use of a social network
approach to formally manipulate and enhance social net-
work effects (that is, individual and network level) to
promote smoking cessation through improved treatment
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communities and social networks is an established in-
dustry strategy. Full time professionals typically manage
a diffuse group of paraprofessionals recruited from the
network itself and trained by the hosting organization
[101]. This model dates back to the earliest days of on-
line networks, such as support forums on Compuserve,
and continues today where companies such as Kaiser
Permanente recruit, incentivize, and train specific key-
players in their online support communities to enhance
discussions, recruit new members, and enforce discip-
line. These individuals (often called ‘peer moderators’ or
‘MVPs’) are usually managed virtually online, critically
enabling the workforce to be spread across time zones.
While this model is pervasive in industry, it has never
been explicitly tested in a rigorous research trial with a
specific focus on increasing adherence. If proven effect-
ive, this approach can be scaled to meet the demand of
even the largest online health communities.
The potential scientific and public health impact of
this study may extend beyond smoking cessation.
Millions of adults use the internet for assistance with
other health behaviors [102] and low levels of treatment
utilization and attrition have been noted across eHealth
studies [28,41,103]. Results from this study may inform
advances in intervention design and implementation,
making existing internet programs more effective across
a range of behavioral risk factors. Even modest increases
in the effectiveness of web-based programs can have
enormous public health impact given the broad reach to
millions of users.
Limitations
We recognize that participants in Groups 1 (WEB) and
2 (WEB + SN) may use NRT on their own and
participants in Groups 1 (WEB) and 3 (WEB + NRT)
may participate in the BecomeAnEX social network. In
an explanatory randomized trial [104] use of unassigned
treatments may be considered ‘contamination’. However,
in the context of a web-based pragmatic randomized
trial such as this, the use of unassigned treatments is un-
avoidable but is expected to be minimal. That is, we an-
ticipate that a small proportion of WEB or WEB + SN
will use NRT on their own without any prompting or
intervention, and a small proportion of WEB or WEB +
NRT will engage in the community without any
prompting or intervention. The aim of our research is to
test the effectiveness of two strategies to increase the
proportion of participants who adhere to all components
of cessation treatment over and above the ‘usual care’
rates of use. Our power analysis, measurement
instruments, and assessment protocols are designed to
account for the ways in which individuals use these
resources in the real-world.Other potential limitations may be difficulty in re-
cruiting racial/ethnic minorities in accordance with tar-
geted enrollment projections, and difficulty in achieving
follow-up rates greater than 75% as projected. In the un-
likely scenario that recruitment lags, we will extend re-
cruitment until targeted recruitment goals are met and/
or modify our analytic plan accordingly. If follow-up
rates are less than 75%, we will use a more intensive
telephone follow-up approach and consider increasing
follow-up incentives as our budget will allow.
Trial status
Study recruitment began in March 2012. The total sam-
ple size is N = 4,000. As of January 2013, 1,700 par-
ticipants have been enrolled. Recruitment is expected to
be completed by summer 2014.
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